These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36952108)

  • 1. Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan.
    Utiel FJB; García AIM; Moyano AP; Oporto FR; García EM; de la Rosa RE
    Int Urol Nephrol; 2023 Oct; 55(10):2629-2637. PubMed ID: 36952108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
    Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
    Bargagli M; Dhayat NA; Anderegg M; Semmo M; Huynh-Do U; Vogt B; Ferraro PM; Fuster DG
    Clin J Am Soc Nephrol; 2020 Jul; 15(7):1007-1014. PubMed ID: 32527945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
    Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O; Chapman AB; Gansevoort RT; Higashihara E; Perrone RD; Torres VE; Blais JD; Zhou W; Ouyang J; Czerwiec FS
    J Am Soc Nephrol; 2017 May; 28(5):1592-1602. PubMed ID: 27920153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
    Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD.
    Akihisa T; Kataoka H; Makabe S; Manabe S; Yoshida R; Ushio Y; Sato M; Yajima A; Hanafusa N; Tsuchiya K; Nitta K; Hoshino J; Mochizuki T
    Nephrol Dial Transplant; 2024 May; 39(6):1008-1015. PubMed ID: 37935473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.
    Grantham JJ; Chapman AB; Blais J; Czerwiec FS; Devuyst O; Gansevoort RT; Higashihara E; Krasa H; Zhou W; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2017 Jun; 32(6):969-975. PubMed ID: 27190355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
    Harskamp LR; Gansevoort RT; Boertien WE; van Oeveren W; Engels GE; van Goor H; Meijer E
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1749-56. PubMed ID: 26231191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Geurts F; Xue L; Kramers BJ; Zietse R; Gansevoort RT; Fenton RA; Meijer E; Salih M; Hoorn EJ;
    Clin J Am Soc Nephrol; 2023 Nov; 18(11):1426-1434. PubMed ID: 37574650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan.
    Yamaguchi T; Higashihara E; Okegawa T; Miyazaki I; Nutahara K
    Clin Exp Nephrol; 2018 Oct; 22(5):1213-1223. PubMed ID: 29789986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
    Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB
    BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
    Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease.
    Cantarelli L; Gutiérrez Valencia M; Leache Alegria L; Sainz Fernandez LC; Erviti Lopez J; Gutiérrez Nicolas F; Nazco Casariego GJ
    Med Clin (Barc); 2024 Jul; 163(1):1-7. PubMed ID: 38616432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
    Xie X; Cai Q; Guo XY; Bai DH; Sheng HZ; Wang BK; Yan K; Lu AM; Wang XR
    Comb Chem High Throughput Screen; 2020; 23(1):6-16. PubMed ID: 31793415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.